Resources designed to be simple

BASAGLAR comes with the BASAGLAR Experience: resources designed to help patients accept, start, and stay on insulin.

In patients with type 1 diabetes, BASAGLAR must be used concomitantly with short-acting insulin.1

SELECT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
All insulin products, including BASAGLAR, cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Monitor potassium levels in patients at risk for hypokalemia if indicated.

Type 2 Diabetes Patient Talking With His Doctor

ACCEPT: Support for your hesitant patients

Are concerns and misconceptions about insulin preventing your patients from starting? When A1C is rising and a patient is still hesitant about starting basal insulin, the BASAGLAR Experience resources may help.

man posing

Insulin Discussion Tool

  • Designed to help guide patients through the importance of different diabetes treatment options
  • Available from your BASAGLAR representative
Injection Demo Kit package

Injection Demonstration Kit and Instructions for Use

  • Helps you demonstrate KwikPen® injection in your office
  • Available from your BASAGLAR representative

Living With Long-Acting Insulin video

  • Helps dispel patient myths about insulin
  • Available on the Beginning BASAGLAR app, online, and as an in-office resource

Watch the Living With Long-Acting Insulin video, which follows Barry through a day in the life of a long- acting insulin beginner. It might help clear up some questions your patients have about what it’s like to start insulin.

SELECT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS

Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including BASAGLAR. If hypersensitivity reactions occur, discontinue BASAGLAR; treat per standard of care and monitor until symptoms and signs resolve. BASAGLAR is contraindicated in patients who have had hypersensitivity reactions to insulin glargine or one of the excipients.

START: Resources are designed to help your patients first starting basal insulin

We have resources that are designed to help with your patient's transition to insulin.

BASAGLAR Sample Kit with needles

BASAGLAR Sample Kit with needles

Lilly is committed to providing the BASAGLAR sample kit to physicians as a resource for patients starting basal insulin. The BASAGLAR sample kit includes a prefilled KwikPen and needles, plus information to access other resources:

  • Information about what to expect
  • Videos to watch for help with injections
  • Savings information
  • Phone number to call with questions and to get connected to the BASAGLAR GoodStart® Program

Train patients on proper use and injection technique before initiating BASAGLAR.

SELECT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS

BASAGLAR prefilled pens must never be shared between patients, even if the needle is changed. Sharing poses a risk of transmission of blood borne pathogens.

BASAGLAR Patient Brochure

BASAGLAR Patient Brochure

  • Important information to help your patients begin BASAGLAR
  • Includes a BASAGLAR Savings Card
  • Ask your BASAGLAR representative

Injection Instruction Video

  • A step-by-step demonstration on how to inject
  • Available on the Beginning BASAGLAR app, online, and as an in-office resource
SELECT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS

All insulin products, including BASAGLAR, cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Monitor potassium levels in patients at risk for hypokalemia if indicated.

STAY: Help reinforce important information at home

BASAGLAR GoodStart Program icon

The BASAGLAR GoodStart Program
Patients enrolled in the BASAGLAR GoodStart Program receive communications from mentors throughout their participation in the program.

  • Provides support, encouragement, and guidance through contact with trained health mentors
  • Designed to help patients establish a positive routine with their newly prescribed medication
  • Patients receive a series of communications covering practical advice, emotional support, and motivational reminders
  • To help your patients enroll, simply have them call 1-855-232-1059

More patients enrolled in the BASAGLAR GoodStart Program refilled their prescriptions compared with patients not enrolled.*



*59% Good Start group (n=4951); 54% control group (n=3266). Data collected over 180 days.14

The control was randomized whereby every fourth eligible patient was placed in a control group and received no GoodStart contact or intervention. Patients were excluded if they were more than 20 days late on their refill or if their scheduled fill date was in the future or within 20 days of the study endpoint.

SELECT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS

Thiazolidinediones (TZDs), which are peroxisome proliferator-activated receptor (PPAR)-gamma agonists, can cause dose-related fluid retention, particularly when used in combination with insulin. Fluid retention may lead to or exacerbate heart failure. These patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of TZD must be considered.

Screenshot of Beginning BASAGLAR App

Beginning BASAGLAR mobile app

  • The Beginning BASAGLAR app lets patients get help right on their phones. Available at the App Store and the Google Play Store, it includes:
  • Injection Instruction Video
  • Access to the BASAGLAR Savings Card
  • Tips to help establish a daily insulin routine
  • Interactive quiz and FAQs
basaglar patient hp

BASAGLAR patient website

Patients can also access many resources on BASAGLAR.com, including the step-by-step Injection Instruction Video and the Instructional Brochure. The website also has:

  • Important phone numbers
  • Savings information
  • Spanish-language site with resources
SELECT SAFETY INFORMATION
ADVERSE REACTIONS

Adverse reactions commonly associated with insulin glargine products (5% or greater incidence) are: hypoglycemia, allergic reactions, injection site reaction, lipodystrophy, pruritus, rash, edema, and weight gain.

Indication and Important Safety Information
Indication

BASAGLAR is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.

LIMITATION OF USE

BASAGLAR is not recommended for the treatment of diabetic ketoacidosis.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

BASAGLAR is contraindicated during episodes of hypoglycemia, and in patients with hypersensitivity to insulin glargine or one of its excipients.

WARNINGS AND PRECAUTIONS

BASAGLAR prefilled pens must never be shared between patients, even if the needle is changed. Sharing poses a risk of transmission of blood borne pathogens.


Changes in insulin strength, manufacturer, type, injection site, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. Any changes in insulin regimen should be made cautiously and only under close medical supervision, and the frequency of blood glucose monitoring should be increased. Due to reports of hypoglycemia and hyperglycemia, advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change the injection site to unaffected areas and closely monitor blood glucose. For patients with type 2 diabetes, dosage adjustments of concomitant anti-diabetic products may be needed.


Hypoglycemia is the most common adverse reaction associated with insulins, including BASAGLAR. Severe hypoglycemia can cause seizures, may be life-threatening, or cause death.


Accidental mix-ups between another insulin glargine product (100 units/mL) and other insulins, particularly rapid-acting insulins, have been reported. To avoid medication errors between BASAGLAR and other insulins, instruct patients to always check the insulin label before each injection.


Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including BASAGLAR. If hypersensitivity reactions occur, discontinue BASAGLAR; treat per standard of care and monitor until symptoms and signs resolve. BASAGLAR is contraindicated in patients who have had hypersensitivity reactions to insulin glargine or one of the excipients.


All insulin products, including BASAGLAR, cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Monitor potassium levels in patients at risk for hypokalemia if indicated.


Thiazolidinediones (TZDs), which are peroxisome proliferator-activated receptor (PPAR)-gamma agonists, can cause dose-related fluid retention, particularly when used in combination with insulin. Fluid retention may lead to or exacerbate heart failure. These patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of TZD must be considered.

ADVERSE REACTIONS

Adverse reactions commonly associated with insulin glargine products (5% or greater incidence) are: hypoglycemia, allergic reactions, injection site reaction, lipodystrophy, pruritus, rash, edema, and weight gain.

DRUG INTERACTIONS

Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. The signs and symptoms of hypoglycemia may be blunted when beta-blockers, clonidine, guanethidine, and reserpine are co-administered with BASAGLAR.

BV HCP ISI 25NOV2019

For more information, please see Full Prescribing Information and Patient Information. Please see Instructions for Use.

References
1. BASAGLAR [Prescribing Information]. Indianapolis, IN: Eli Lilly and Company. 2. Rosenstock J, Hollander P, Bhargava A, et al. Diabetes Obes Metab. 2015;17:734-741. 3. Data on file, Lilly USA, LLC. BAS20160408A. 4. Data on file, Lilly USA, LLC. BAS20160811B. 5. Lantus [Prescribing Information]. Bridgewater, NJ: sanofi-aventis U.S. LLC; 2018. 6. Linnebjerg H, Lam EC, Seger ME, et al. Diabetes Care. 2015;38:2226-2233. 7. Blevins TC, Dahl D, Rosenstock J, et al. Diabetes Obes Metab. 2015;17:726-733. 8. Data on file, Lilly USA, LLC. BAS20151103E. 9. Data on file, Lilly USA, LLC. BAS20160811A. 10. Gerstein HC, Yale JF, Harris SB, et al. Diabet Med. 2006;23:736-742. 11. BASAGLAR KwikPen [Instructions for Use]. Indianapolis, IN: Eli Lilly and Company. 12. Hirsch LJ, Gibney MA, Qu S, et al. Curr Med Res Opin. 2010;26(6):1531-1541. 13. Fischer MA, Stedman MR, Lii J, et al. J Gen Intern Med. 2010;25(4):284-290. 14. Data on file, Lilly USA, LLC. DOF-BV-US-0002.